Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 15/20 | 0.70 |
| ▸ | CA1 | P00915 | 11/20 | 0.70 |
| ▸ | CA9 | Q16790 | 13/20 | 0.59 |
| ▸ | CA12 | O43570 | 10/20 | 0.59 |
| ▸ | CA14 | Q9ULX7 | 4/20 | 0.59 |
| ▸ | CA4 | P22748 | 3/20 | 0.59 |
| ▸ | CA7 | P43166 | 4/20 | 0.52 |
| ▸ | CA5A | P35218 | 3/20 | 0.52 |
| ▸ | CA6 | P23280 | 2/20 | 0.52 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.52 |
| ▸ | CA3 | P07451 | 1/20 | 0.52 |
| ▸ | PLA2G7 | Q13093 | 1/20 | 0.52 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.52 |
| ▸ | NOS1 | P29475 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2398133 | 0.83 | CA2 (1.00) | CA2CA1CA9CA12CA14 | |
| SCHEMBL30084552 | 0.81 | LMNA (0.54) | CA2CA1CA9CA12CA14 | |
| SCHEMBL3677379 | 0.81 | LMNA (0.54) | CA2CA1CA9CA12CA14 | |
| SCHEMBL8960195 | 0.79 | CA1 (0.41) | CA2CA1CA9CA12CA14 | |
| Benzenesulfonamide SCHEMBL5671646 | 0.79 | CA2 (0.76) | CA2CA1CA9CA12CA14 | |
| SCHEMBL3667501 | 0.77 | ALDH1A1 (0.42) | CA2CA1 | |
| SCHEMBL30628286 | 0.77 | ALDH1A1 (0.42) | CA2CA1 | |
| SCHEMBL19122490 | 0.77 | CA2 (0.39) | CA2CA1CA9CA12CA14 | |
| SCHEMBL486222 | 0.77 | ALDH1A1 (0.52) | CA2CA1CA9CA12CA14 | |
| SCHEMBL3371316 | 0.77 | ALDH1A1 (0.57) | CA2CA1CA9CA12LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024115549-A1 | ARYL- AND HETEROARYL-SULFONAMIDE DERIVATIVES AS CCR8 MODULATORS | IDORSIA PHARMACEUTICALS LTD (CH) | 2024-06-06 | — | — | WO | claimed |
| US-20240368189-A1 | Modulators of Cystic Fibrosis Transmembrane Conductance Regulator, Pharmaceutical Compositions, Methods of Treatment, and Process for Making the Modulators | VERTEX PHARMA (US) | 2024-11-07 | — | — | US | disclosed |
| WO-2024115549-A1 | ARYL- AND HETEROARYL-SULFONAMIDE DERIVATIVES AS CCR8 MODULATORS | IDORSIA PHARMACEUTICALS LTD (CH) | 2024-06-06 | — | — | WO | disclosed |
| US-11866450-B2 | Modulators of Cystic Fibrosis Transmembrane Conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulators | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2024-01-09 | — | — | US | disclosed |
| CN-117285547-A | Macrocyclic compounds as modulators of CFTR, pharmaceutical compositions thereof, their use and methods of preparation | 弗特克斯药品有限公司 | 2023-12-26 | — | — | CN | disclosed |
| CN-112004817-B | Macrocyclic compounds as modulators of CFTR, pharmaceutical compositions thereof, their use and methods of preparation | 弗特克斯药品有限公司 | 2023-06-23 | — | — | CN | disclosed |
| EP-4198037-A1 | MACROCYCLES AS MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR, PHARMACEUTICAL COMPOSITIONS THEREOF AND THEIR USE IN THE TREATMENT OF CYCSTIC FIBROSIS | Vertex Pharmaceuticals Incorporated (US) | 2023-06-21 | — | — | EP | disclosed |
| EP-4198037-A1 | MACROCYCLES AS MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR, PHARMACEUTICAL COMPOSITIONS THEREOF AND THEIR USE IN THE TREATMENT OF CYCSTIC FIBROSIS | Vertex Pharmaceuticals Incorporated (US) | 2023-06-21 | — | — | EP | disclosed |
| EP-3752510-B1 | MACROCYCLES AS MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR, PHARMACEUTICAL COMPOSITIONS THEREOF, THEIR USE IN THE TREATMENT OF CYCSTIC FIBROSIS, AND PROCESS FOR MAKING THEM | VERTEX PHARMA (US) | 2022-12-07 | — | — | EP | disclosed |
| EP-3752510-B1 | MACROCYCLES AS MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR, PHARMACEUTICAL COMPOSITIONS THEREOF, THEIR USE IN THE TREATMENT OF CYCSTIC FIBROSIS, AND PROCESS FOR MAKING THEM | VERTEX PHARMA (US) | 2022-12-07 | — | — | EP | disclosed |
| CN-1501911-A | Phenethanolamine derivatives for treatment of respiratory diseases | — | 2004-06-02 | — | — | CN | disclosed |
| EP-1395604-A1 | NOVEL ANTI INFLAMMATORY 17.ALPHA.-HETEROCYCLIC-ESTERS OF 17.BETA.-CARBOTHIOATE ANDROSTANE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2004-03-10 | — | — | EP | disclosed |
| EP-1383786-A1 | ANTI-INFLAMMATORY 17.BETA.-CARBOTHIOATE ESTER DERIVATIVES OF ANDROSTANE WITH A CYCLIC ESTER GROUP IN POSITION 17.ALPHA | GLAXO GROUP LIMITED (GB) | 2004-01-28 | — | — | EP | disclosed |
| EP-1370521-A1 | FORMANILIDE DERIVATIVES AS BETA2-ADRENORECEPTOR AGONISTS | GLAXO GROUP LIMITED (GB) | 2003-12-17 | — | — | EP | disclosed |
| EP-1360174-A1 | PHENETHANOLAMINE DERIVATIVES FOR TREATMENT OF RESPIRATORY DISEASES | GLAXO GROUP LIMITED (GB) | 2003-11-12 | — | — | EP | disclosed |
| WO-2003035668-A2 | NOVEL ANTI-INFLAMMATORY ANDROSTANE DERIVATIVES -17-CARBOXY-LACTONE SUBSTITUTED STEROIDS WITH AN ARYL-CARBOXYLIC ESTER IN POSITION 17.ALPHA | GLAXO GROUP LIMITED (GB) | 2003-05-01 | — | — | WO | disclosed |
| WO-2002100879-A1 | NOVEL ANTI-INFLAMMATORY 17.ALPHA.-HETEROCYCLIC-ESTERS OF 17.BETA.CARBOTHIOATE ANDROSTANE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2002-12-19 | — | — | WO | disclosed |
| WO-2002088167-A1 | ANTI-INFLAMMATORY 17.BETA.-CARBOTHIOATE ESTER DERIVATIVES OF ANDROSTANE WITH A CYCLIC ESTER GROUP IN POSITION 17.ALPHA | GLAXO GROUP LIMITED (GB) | 2002-11-07 | — | — | WO | disclosed |
| WO-2002076933-A1 | FORMAILIDE DERIVATIVES AS BETA2-ADRENORECEPTOR AGONISTS | GLAXO GROUP LIMITED (GB) | 2002-10-03 | — | — | WO | disclosed |
| WO-2002066422-A1 | PHENETHANOLAMINE DERIVATIVES FOR TREATMENT OF RESPIRATORY DISEASES | GLAXO GROUP LIMITED (GB) | 2002-08-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240368189-A1 | Modulators of Cystic Fibrosis Transmembrane Conductance Regulator, Pharmaceutical Compositions, Methods of Treatment, and Process for Making the Modulators | CFTR, SLC26A4, ABCB11 | CA2 1541/4885CA1 4785/4885CA9 2826/4885 |
| US-11866450-B2 | Modulators of Cystic Fibrosis Transmembrane Conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulators | CFTR, SLC26A4, ABCB11 | CA2 1541/4885CA1 4785/4885CA9 2826/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.